Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Revive Therapeutics Ltd (RVV.CN)

Revive Therapeutics Ltd (RVV.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 4,186
  • Shares Outstanding, K 418,564
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,619 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.24
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.58
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.01
  • Most Recent Earnings $0.00 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    SIC-2834 Pharmaceutical Preparations

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0050 +100.00%
on 12/02/24
0.0150 -33.33%
on 11/27/24
+0.0050 (+100.00%)
since 11/01/24
3-Month
0.0050 +100.00%
on 12/02/24
0.0150 -33.33%
on 11/27/24
unch (unch)
since 09/04/24
52-Week
0.0050 +100.00%
on 12/02/24
0.0400 -75.00%
on 01/25/24
-0.0250 (-71.43%)
since 12/04/23

Most Recent Stories

More News
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

RVV.CN : 0.0100 (unch)
RVVTF : 0.0070 (+6.06%)
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

RVV.CN : 0.0100 (unch)
RVVTF : 0.0070 (+6.06%)
Stocks in play: Revive Therapeutics Ltd

Announced today that the U.S. Food & Drug Administration has granted the Company’s Type C meeting request ...

RVV.CN : 0.0100 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, July 25, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty...

RVVTF : 0.0070 (+6.06%)
RVV.CN : 0.0100 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

FDA accepts Company’s Data Access Plan to determine potential new clinical endpoints to support Emergency Use Authorization...

RVVTF : 0.0070 (+6.06%)
RVV.CN : 0.0100 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

The Company submits Data Access Plan to the FDA to determine potential new clinical endpoints to support Emergency Use Authorization...

RVVTF : 0.0070 (+6.06%)
RVV.CN : 0.0100 (unch)
Stocks in play: Revive Therapeutics Ltd

Provides an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate ...

RVV.CN : 0.0100 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

The Company received positive comments from the FDA to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, May 26,...

RVVTF : 0.0070 (+6.06%)
RVV.CN : 0.0100 (unch)
Stocks in play: Revive Therapeutics Ltd

Provides an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate ...

RVV.CN : 0.0100 (unch)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

The Company submitted request to the FDA to determine potential new clinical endpoints for FDA consideration for EUA...

RVVTF : 0.0070 (+6.06%)
RVV.CN : 0.0100 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as...

See More

Key Turning Points

3rd Resistance Point 0.0100
2nd Resistance Point 0.0100
1st Resistance Point 0.0100
Last Price 0.0100
1st Support Level 0.0100
2nd Support Level 0.0100
3rd Support Level 0.0100

See More

52-Week High 0.0400
Fibonacci 61.8% 0.0266
Fibonacci 50% 0.0225
Fibonacci 38.2% 0.0184
Last Price 0.0100
52-Week Low 0.0050

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar